366
Views
27
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: CLINICAL TRANSLATIONAL THERAPEUTICS

Clinical Significance of GPR56, Transglutaminase 2, and NF-κB in Esophageal Squamous Cell Carcinoma

, , , , , , & show all
Pages 42-48 | Published online: 27 Sep 2010
 

Abstract

Proteins do not operate as individual units, and components of intracellular canonical pathways often cross talk in tumor genesis. We hypothesized that G-protein-coupled receptor 56 (GPR56), transglutaminase (TG2), and nuclear factor-κB (NF-κB) may collaborate in interconnected pathways and contribute to the aggressive behavior of esophageal squamous cell carcinoma (ESCC). Immunohistochemical analysis of GPR56, TG2, and NF-κB was carried out using ESCC tissue microarrays. Immunostaining of all the three proteins revealed a significant increase in their expression in ESCCs as compared with normal epithelia and correlated with their concomitant expression. A significant correlation between GPR56, TG2, and NF-κB was observed that correlated with nodal metastasis and tumor invasion in ESCCs.

ACKNOWLEDGMENTS

The financial support from the Department of Science and Technology, Government of India, is gratefully acknowledged. Tasneem Kausar and Raghibul Hasan are the recipients of fellowships from the Council of Scientific and Industrial Research and Department of Biotechnology, India, respectively.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.